Development and validation of a highly sensitive second derivative synchronous fluorescence spectroscopic method for the simultaneous determination of elbasvir and grazoprevir in pharmaceutical preparation and human plasma

Elbasvir and grazoprevir combination has been newly approved for the treatment of patients infected with hepatitis C virus.